NCT05068440 2026-03-25Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibBeOne MedicinesPhase 2 Completed65 enrolled 14 charts